Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 5/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 4/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6594049 | 0.87 | CRHBP (0.52) | CRHBPCRHR2ERN1ABCB1ABCC1 | |
| SCHEMBL6594055 | 0.87 | CRHBP (0.52) | CRHBPCRHR2ERN1ABCB1ABCC1 | |
| SCHEMBL6079981 | 0.82 | APP (0.49) | ERN1APP | |
| SCHEMBL6080243 | 0.81 | ABCB1 (0.38) | ERN1ABCB1ABCC1APP | |
| SCHEMBL6080426 | 0.81 | NQO2 (0.43) | ABCC1 | |
| SCHEMBL6079934 | 0.81 | MAPT (0.43) | APP | |
| SCHEMBL6081303 | 0.81 | DHODH (0.43) | ABCC1 | |
| SCHEMBL6080427 | 0.81 | LMNA (0.44) | APP | |
| SCHEMBL6079854 | 0.78 | CTSB (0.41) | APP | |
| SCHEMBL6079541 | 0.78 | ALDH1A1 (0.40) | CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | CRHBP 4731/4885CRHR2 4804/4885ERN1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.